Protalix BioTherapeutics Inc (FRA:PBDA)
€ 1.0305 0.022 (2.18%) Market Cap: 87.92 Mil Enterprise Value: 70.56 Mil PE Ratio: 0 PB Ratio: 3.28 GF Score: 42/100

Q3 2022 Protalix Biotherapeutics Inc Earnings Call Transcript

Nov 14, 2022 / 01:30PM GMT
Release Date Price: €0.9958 (-0.34%)
Operator

Greetings, and welcome to the Protalix BioTherapeutics Third Quarter 2022 Financial and Business Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce to your host, Mr. Chuck Padala of LifeSci Advisors, Investor Relations for Protalix. Sir, you may begin your conference.

Charles Padala

Thank you, operator, and welcome to the Protalix BioTherapeutics Third Quarter 2022 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO of Protalix; and Eyal Rubin, Senior Vice President and Chief Financial Officer.

A press release announcing the results and the update was issued this morning and is available on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot